A Blue Cross Blue Shield study of one decade worth of claims for Saxenda and Wegovy found 58% of patients quit the weight-loss drugs after 12 weeks.

Saxenda is available as 6mg/mL strength solution for subcutaneous injection. It is supplied as 3mL multi-dose, prefilled pens in 3- and 5-count cartons; each individual pen delivers doses of 0.6mg ...

A Blue Cross Blue Shield study of one decade worth of claims for Saxenda and Wegovy found 58% of patients quit the weight-loss drugs after 12 weeks.

Weight-loss injections like Ozempic costs about $1,200 monthly without insurance coverage. Though it can be as cheap as $25 monthly with coverage, it costs employers millions.

INDIANAPOLIS — Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival ...

--Novo Nordisk today announced that the U.S. Food and Drug Administration approved an updated label for Saxenda ® injection 3 mg for use in the treatment of obesity in adolescents with a body ...

Novo Nordisk’s obesity drug Saxenda, which shares the ingredient liraglutide with the company's diabetes treatment Victoza, has been shown to reduce appetite.

Novo Nordisk's injectable 3-mg liraglutide (Saxenda) was approved for chronic weight management in teens with obesity, the FDA announced late Friday. The GLP-1 receptor agonist, which was first ...

Risk of some cannibalisation between Wegovy, Saxenda New study data shows sustained weight loss over 2 years Novo will launch Wegovy in the U.S. on June 10 Shares up 0.56% Adds details, results ...

A report by Blue Shield notes that more than half of people on weight loss medications such as Wegovy and Saxenda stop taking the drugs before they can reap the benefits ...